
Atropos Health and Kythera Labs Partner to Expand Access to Real-World Data to Advance Oncology
With the Kythera Labs collaboration, the Atropos Evidence Network continues to expand, adding the high-quality datasets needed to generate actionable insights. By utilizing Atropos Health's Real World Data Score® (RWDS) & Real World Fitness Score® (RWFS), users can select the dataset that is the most suitable to answer each question.
Kythera Labs' Oncology Event asset is a rich, high-fidelity dataset that provides comprehensive insights into the oncology care continuum, including patient interactions, treatment decisions, and provider engagements. Built from Kythera Labs' Remastered Source Data, the Oncology Event asset utilizes Kythera Labs' dynamic common data model and proprietary methodologies to ensure accuracy and depth. Through Atropos Evidence Network, organizations can quickly access actionable insights that support faster and more confident decisions in oncology research, clinical trials, and patient care.
'Growing the multimodal oncology network increases the opportunity for Atropos Evidence Network members to find more 'fit-for-purpose' data' said Dr. Brigham Hyde, CEO and co-founder of Atropos Health. 'Together with Kythera Labs, we will better enable healthcare organizations to accelerate and improve clinical decision making, clinical research productivity and clinical trial site selection and recruitment with novel evidence-based insights.'
The Atropos Evidence Network creates a market for data holders to expand the reach of these de-identified assets to a broader audience. Data contributors receive transparent, analytically driven feedback on usage and their own data quality and strengths. Atropos Health is the connection between real-world evidence (RWE) and actionable clinical analytics.
With the addition of Kythera Lab's purpose-built, remastered Real World Data, comprehensive, enriched insights into the full oncology care continuum, including patient interactions, provider engagements, and treatment nuances, will help spur innovation and optimize patient care strategies.
"At Kythera Labs, we are committed to closing the gaps between R&D and care delivery, moving insights from the clinical bedside to the research bench,' said Jeff McDonald, CEO and co-founder of Kythera Labs. 'Partnerships like this are integral to making progress within the field of oncology. By collaborating with Atropos Health and providing access to our enriched and analytics-ready data assets, we hope to help Evidence Network users reach answers faster and more cost-efficiently.'
The Atropos Evidence Network operates on GENEVA OS™ (Generative Evidence Acceleration Operating System), a federated model, forming secure, cloud-based connections between healthcare data proprietors and clinical insight seekers across the healthcare ecosystem. De-identified data doesn't change hands - institutional members of the network, such as a physician or researcher, can pose clinical questions to a variety of datasets. Within 48 hours, the user receives a novel retrospective observational study in response.
About Atropos Health
Atropos Health is the developer of GENEVA OS™ , the operating system for rapid healthcare evidence across a robust network of real-world data. Healthcare and life science organizations work with Atropos Health to close evidence gaps from bench to bedside, improving individual patient outcomes with data-driven care, expediting research that advances the field of medicine, and more. We aim to transform healthcare with timely, relevant real-world evidence.
To learn more about Atropos Health, visit www.atroposhealth.com or connect through LinkedIn or follow on X (Twitter) @AtroposHealth.
About Kythera Labs
Kythera Labs is a data technology company that unifies data science and data technology to enable higher fidelity in healthcare data for Healthcare and Life Sciences organizations. Our multi-source data captures over 310M de-identified unique individuals and our technology is built for RWD users to integrate, access, analyze and find answers.
Learn more at www.kytheralabs.com or follow Kythera Labs on LinkedIn.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
10 hours ago
- Yahoo
Corcept (CORT) Advances Ovarian Cancer Therapy with FDA Filing for Relacorilant
Corcept Therapeutics Incorporated (NASDAQ:CORT) is one of the growth stocks that could double by 2027. On July 14, CORT submitted an FDA application for relacorilant to treat platinum-resistant ovarian cancer, based on promising Phase 2 and 3 trial data. A professional scientist in a laboratory, visually demonstrating the development of Microbiome therapeutics platform. Patients receiving the drug with nab-paclitaxel experienced notable improvements in survival outcomes without added safety risks. With relacorilant already designated as an orphan drug and a decision date set for December 30, 2025, this milestone marks Corcept's second active NDA submission. Relacorilant modulates cortisol activity via glucocorticoid receptors and has shown strong clinical potential. Backed by robust financials, including a 128% stock return over the past year and a current ratio of 3.07, Corcept is well-positioned to target the estimated 20,000 U.S. patients needing new therapies for platinum-resistant disease annually. If approved, this drug could significantly enhance treatment options and expand the company's oncology portfolio. Corcept Therapeutics Incorporated (NASDAQ:CORT) is a biopharma firm specializing in therapies that regulate cortisol, a key hormone in body function. Its lead product, Korlym, is FDA-approved for treating Cushing's syndrome, a condition caused by excess cortisol. While we acknowledge the potential of CORT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
10 hours ago
- Yahoo
Zai Lab Ltd (ZLAB) Delivers Positive Results for Potential Gastric Cancer Treatment
Zai Lab Ltd (NASDAQ:ZLAB) is one of the best biotech stocks to buy according to billionaire Steve Cohen. On June 30, Leerink Partners raised its price target for the stock to $75 from $73. The research firm also reiterated an 'Outperform' rating on the stock. A doctor in a white coat discussing clinical trial results with a patient in an oncology practice. The research firm hiked its price target following positive Phase III trial results from the FORTITUDE-101 study. The study was evaluating bemarituzumab as a first-line FGFR2B-positive gastric cancer treatment. The candidate drug, developed in partnership with Amgen, met its primary endpoint while demonstrating a significant and clinically meaningful overall survival benefit compared to placebo plus chemotherapy. Following the positive results, Zai Labs plans a second Phase III trial, FORTITUDE-102, which will evaluate bemarituzumab in combination with chemotherapy and nivolumab. The company expects top-line data in the second half of the year that will affirm the candidate drug as a first-line treatment for gastric cancer. It also plans to file for regulatory approval in China following the positive results. Zai Lab Ltd (NASDAQ:ZLAB) is a biopharmaceutical company that discovers, develops, and commercializes innovative medicines for oncology, autoimmune disorders, infectious diseases, and neurological disorders. While we acknowledge the potential of ZLAB as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Goldman Sachs REIT Stocks: Top 12 Stock Picks. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
10 hours ago
- Yahoo
Incyte Corp (INCY) Price Target Hiked at UBS on Sales and Earnings Growth Prospects
Incyte Corporation (NASDAQ:INCY) is one of the best biotech stocks to buy according to billionaire Steve Cohen. On July 15, UBS reiterated a 'Neutral' rating on the stock and increased its price target to $62 from $61. A pharmacist preparing a dose of an immuno-oncology agent for research use. The price hike comes as UBS expects higher sales for Incyte's Niktimvo, a treatment for chronic Graft-versus-Host Disease (cGVHD). Amid the expected higher sales, UBS has revised its 2026 earnings per share estimate of $6.36 from $6.26. UBS also maintained a 9.5x price-to-earnings multiple on Incyte, as it expects the company's second-quarter earnings call to provide clarity on the company's strategic direction. The company's pipeline has already received a boost following the FDA's extension of the review for ruxolitinib cream for pediatric atopic dermatitis. Incyte Corporation (NASDAQ:INCY) is a biopharmaceutical company that discovers, develops, and commercializes proprietary therapies in oncology and inflammation & autoimmunity. It also boasts a growing portfolio of treatments for other diseases, including those in dermatology. While we acknowledge the potential of INCY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Goldman Sachs REIT Stocks: Top 12 Stock Picks. Disclosure: None. This article is originally published at Insider Monkey.